579-Oncolytic Virus Triggers Persistent T Cell Immunity
This research article investigates how a single oncolytic virus treatment can trigger a robust and lasting immune response in patients with recurrent glioblastoma. Using advanced spatial technologies like CODEX and Xenium, the authors demonstrate that the therapy causes T cells to infiltrate deeply into tumor regions, where they remain active for months or even years. The study highlights that the expansion of pre-existing T cell clones is a key driver of clinical success, directly correlating with improved patient survival outcomes. Notably, the remaining viral elements were found only in…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.